All In Biotech

NDA 011245 · Bracco

Gastrografin

Diatrizoate Meglumine, Diatrizoate Sodium · Oral, Rectal

Last checked: Nov 20, 2026Latest source record: Aug 29, 2005 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1958

Jan 17, 1958

Approved uses

2

Original approval plus efficacy supplements

Registered trials

14

4 Phase 3, 1 recruiting

FAERS reports

372

260 serious, 54 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 4, 2021.

INDICATIONS AND USAGE Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous. Gastrografin may also be used as an adjunct to contrast enhancement in computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology.

Therapeutic areas: Gastroenterology and liver

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 14, 1983 Supplement 20 · Efficacy
  • Jan 17, 1958 Original approval · Type 3 - New Dosage Form
1 products under this application
  • GASTROGRAFIN · DIATRIZOATE MEGLUMINE 66%; DIATRIZOATE SODIUM 10% · SOLUTION, ORAL, RECTAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Diatrizoate Meglumine" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • urticaria31
  • diarrhoea27
  • nausea24
  • vomiting23
  • no adverse event22
  • pruritus19
  • drug ineffective17
  • off label use17
  • dyspnoea16
  • rash13
  • sepsis12
  • hypotension11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20059
200612
20077
200827
200915
201027
201122
201220
201317
201416
201520
201630
201722
201822
201919
202013
202125
202217
202314
20247
20258
20263

Recalls

2 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

  • Jun 21, 2013 · Class II · Terminated

    Presence of foreign substance: One lot of the product may contain black foreign particles

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Gastrografin* (Diatrizoate Meglumine, Sodium*) · HCPCS Q9963

2024 spending

$7K

Beneficiaries

752

818 claims

Per beneficiary

$9

2024 ASP limit $0.22 per unit

View as table
YearSpending
2020$11,616
2021$7,733
2022$8,624
2023$7,198
2024$7,027

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 90 on PubMed

Sponsor: Bracco

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.